Ballentine Partners LLC Sells 2,498 Shares of The Cooper Companies, Inc. $COO

Ballentine Partners LLC lessened its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 40.2% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,717 shares of the medical device company’s stock after selling 2,498 shares during the period. Ballentine Partners LLC’s holdings in Cooper Companies were worth $265,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Zions Bancorporation National Association UT purchased a new stake in Cooper Companies during the 1st quarter worth about $33,000. City Holding Co. purchased a new position in shares of Cooper Companies in the first quarter worth $34,000. GKV Capital Management Co. Inc. bought a new stake in Cooper Companies during the 1st quarter valued at $40,000. Larson Financial Group LLC boosted its position in Cooper Companies by 1,071.0% during the 1st quarter. Larson Financial Group LLC now owns 726 shares of the medical device company’s stock valued at $61,000 after buying an additional 664 shares during the period. Finally, HM Payson & Co. lifted its holdings in Cooper Companies by 147.4% in the 1st quarter. HM Payson & Co. now owns 893 shares of the medical device company’s stock worth $75,000 after buying an additional 532 shares during the period. Institutional investors own 24.39% of the company’s stock.

Insider Buying and Selling at Cooper Companies

In other Cooper Companies news, EVP Brian G. Andrews bought 1,525 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The shares were purchased at an average cost of $65.68 per share, for a total transaction of $100,162.00. Following the transaction, the executive vice president owned 22,191 shares of the company’s stock, valued at $1,457,504.88. This represents a 7.38% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Gerard H. Warner III purchased 1,450 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The shares were bought at an average price of $69.23 per share, for a total transaction of $100,383.50. Following the acquisition, the chief operating officer directly owned 18,319 shares in the company, valued at $1,268,224.37. This trade represents a 8.60% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 15,975 shares of company stock valued at $1,079,566 over the last quarter. 1.98% of the stock is owned by corporate insiders.

Cooper Companies Trading Up 1.0%

Shares of Cooper Companies stock opened at $67.55 on Monday. The stock has a market capitalization of $13.43 billion, a PE ratio of 33.28, a P/E/G ratio of 1.77 and a beta of 0.97. The Cooper Companies, Inc. has a 1-year low of $61.78 and a 1-year high of $111.44. The company’s fifty day simple moving average is $70.13 and its 200-day simple moving average is $74.48. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.12 and a quick ratio of 1.24.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Wednesday, August 27th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.07 by $0.03. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. The firm had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the prior year, the company posted $0.96 earnings per share. The company’s revenue for the quarter was up 5.7% compared to the same quarter last year. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, equities analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Cooper Companies announced that its board has initiated a stock buyback program on Wednesday, September 17th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical device company to buy up to 15.4% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s management believes its shares are undervalued.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on COO. BNP Paribas raised shares of Cooper Companies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 22nd. Morgan Stanley set a $76.00 price objective on Cooper Companies and gave the company an “equal weight” rating in a research report on Thursday, August 28th. Mizuho dropped their target price on shares of Cooper Companies from $105.00 to $90.00 and set an “outperform” rating on the stock in a report on Wednesday, July 16th. Robert W. Baird decreased their price target on shares of Cooper Companies from $97.00 to $85.00 and set an “outperform” rating for the company in a research note on Thursday, August 28th. Finally, Piper Sandler reduced their price objective on Cooper Companies from $105.00 to $83.00 and set an “overweight” rating for the company in a research report on Thursday, August 28th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Cooper Companies currently has an average rating of “Moderate Buy” and a consensus target price of $86.64.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.